Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMAL MEHTA

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1639374549
CMS profile
29333
Location
HEMET, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,975.44

147 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,975.44 147

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMAL MEHTA

NPI 1639374549 · CMS profile ID 29333

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

HEMET, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639374549?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMAL MEHTA, NPI 1639374549, CMS profile ID 29333. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639374549?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). AMAL MEHTA, NPI 1639374549, CMS profile ID 29333. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639374549?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
AMAL MEHTA, NPI 1639374549, CMS profile ID 29333, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1639374549?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

147 matching records · $2,975.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 147 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–147 of 147.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ANI Pharmaceuticals, Inc. $17.6304/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248610963 CMS
ABBVIE INC. $19.3704/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203065800 CMS
Lilly USA, LLC $21.3904/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186507087 CMS
PFIZER INC. $21.9004/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230015803 CMS
AstraZeneca Pharmaceuticals LP $20.0704/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206268004 CMS
ABBVIE INC. $18.8504/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203065798 CMS
Amgen Inc. $21.3403/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228306083 CMS
Alexion Pharmaceuticals, Inc. $21.5703/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202961386 CMS
Janssen Biotech, Inc. $3.1403/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174630066 CMS
ABBVIE INC. $10.1403/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203065796 CMS
UCB, Inc. $3.4003/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224702876 CMS
UCB, Inc. $22.8303/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224702880 CMS
PFIZER INC. $21.2203/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230031150 CMS
ABBVIE INC. $10.3303/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203065794 CMS
ABBVIE INC. $9.5303/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203065792 CMS
ABBVIE INC. $16.6503/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203065790 CMS
Janssen Biotech, Inc. $4.9403/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174629797 CMS
Lilly USA, LLC $17.8303/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186502821 CMS
UCB, Inc. $29.1403/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224702197 CMS
ABBVIE INC. $8.4103/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203065788 CMS
UCB, Inc. $18.8103/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224702193 CMS
ABBVIE INC. $11.8603/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203065786 CMS
Amgen Inc. $6.4602/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227180804 CMS
GlaxoSmithKline, LLC. $18.3802/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191411408 CMS
ABBVIE INC. $12.8302/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203065782 CMS
ABBVIE INC. $6.9802/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203065784 CMS
Novartis Pharmaceuticals Corporation $14.1102/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200704973 CMS
ABBVIE INC. $8.4702/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203065780 CMS
UCB, Inc. $23.9602/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224702190 CMS
AstraZeneca Pharmaceuticals LP $17.5502/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207238117 CMS
Lilly USA, LLC $20.4102/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186507085 CMS
Janssen Biotech, Inc. $9.3202/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174630021 CMS
Amgen Inc. $5.4801/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227180806 CMS
GlaxoSmithKline, LLC. $31.2101/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191409056 CMS
Novartis Pharmaceuticals Corporation $20.4501/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200704969 CMS
Novartis Pharmaceuticals Corporation $0.8201/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200704971 CMS
Janssen Biotech, Inc. $36.8901/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174629264 CMS
Janssen Biotech, Inc. $5.1901/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174629689 CMS
UCB, Inc. $29.8701/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224702186 CMS
Amgen Inc. $5.1401/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227180802 CMS
GlaxoSmithKline, LLC. $24.7101/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190663165 CMS
ANI Pharmaceuticals, Inc. $23.9401/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248661167 CMS
PFIZER INC. $22.2301/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230039975 CMS
ABBVIE INC. $9.7401/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203065778 CMS
Alexion Pharmaceuticals, Inc. $20.4601/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202927472 CMS
Lilly USA, LLC $22.0201/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186473141 CMS
PFIZER INC. $20.6101/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230089695 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,690.14 90
PY2020 $1,421.75 22
PY2021 $330.24 12
PY2022 $1,791.35 94
PY2023 $2,199.11 117
PY2024 $2,268.31 110
PY2025 $2,975.44 147

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,912,033.28 31
PY2024 Recipient $104.58 1
PY2024 Principal investigator $879,218.16 7
PY2023 Principal investigator $204,687.00 4
PY2022 Principal investigator $15,639.81 2
PY2021 Principal investigator $70,017.01 21
PY2020 Principal investigator $168,850.30 21
PY2019 Principal investigator $196,226.24 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $35,981.11 12/04/2025 Non-covered Recipient Entity
AMAL MEHTA MD APMC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202526476
Principal investigator 1 ABBVIE INC. $24,327.45 11/06/2025 Non-covered Recipient Entity
AMAL MEHTA MD APMC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202523349
Principal investigator 1 GlaxoSmithKline, LLC. $31,079.70 11/05/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192161247
Principal investigator 1 ABBVIE INC. $1,350.00 10/30/2025 Non-covered Recipient Entity
CV MEHTA MD MEDICAL CORPORATION
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202519675
Principal investigator 1 ABBVIE INC. $79,505.67 10/09/2025 Non-covered Recipient Entity
CV MEHTA MD MEDICAL CORPORATION
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202513705
Principal investigator 1 ABBVIE INC. $975.00 10/02/2025 Non-covered Recipient Entity
CV MEHTA MD MEDICAL CORPORATION
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202513035
Principal investigator 1 GlaxoSmithKline, LLC. $11,184.30 10/02/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192162025
Principal investigator 1 GlaxoSmithKline, LLC. $38,559.60 09/03/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192162030
Principal investigator 1 GlaxoSmithKline, LLC. $34,351.20 08/01/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192161229
Principal investigator 1 ABBVIE INC. $35,820.92 07/02/2025 Non-covered Recipient Entity
CV MEHTA MD MEDICAL CORPORATION
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202496271
Principal investigator 1 GlaxoSmithKline, LLC. $30,955.50 07/02/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192161240
Principal investigator 1 Amgen Inc. $679.00 07/01/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis No dispute reported 06/30/2026 1246644361
Principal investigator 1 ABBVIE INC. $525.00 06/26/2025 Non-covered Recipient Entity
CV MEHTA MD MEDICAL CORPORATION
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202493217
Principal investigator 1 Eli Lilly and Company $24,041.00 06/24/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187876123
Principal investigator 1 GlaxoSmithKline, LLC. $55,053.90 06/04/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192161261
Principal investigator 1 ABBVIE INC. $150.00 05/22/2025 Non-covered Recipient Entity
CV MEHTA MD MEDICAL CORPORATION
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485939
Principal investigator 1 ABBVIE INC. $1,890.00 05/22/2025 Non-covered Recipient Entity
CV MEHTA MD MEDICAL CORPORATION
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485941
Principal investigator 1 ABBVIE INC. $1,917.00 05/21/2025 Non-covered Recipient Entity
CV MEHTA MD MEDICAL CORPORATION
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485667
Principal investigator 1 ABBVIE INC. $6,375.00 05/21/2025 Non-covered Recipient Entity
CV MEHTA MD MEDICAL CORPORATION
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485669
Principal investigator 1 ABBVIE INC. $1,400.00 05/21/2025 Non-covered Recipient Entity
CV MEHTA MD MEDICAL CORPORATION
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485671
Principal investigator 1 GlaxoSmithKline, LLC. $22,142.70 05/09/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192161265
Principal investigator 1 ABBVIE INC. $9,150.00 05/07/2025 Non-covered Recipient Entity
CV MEHTA MD MEDICAL CORPORATION
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202483897
Principal investigator 1 Amgen Inc. $100,093.61 04/24/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639729
Principal investigator 1 GlaxoSmithKline, LLC. $22,767.30 04/02/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192161252
Principal investigator 1 GlaxoSmithKline, LLC. $22,182.30 03/07/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192161257
Principal investigator 1 Eli Lilly and Company $99,231.00 02/11/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875801
Principal investigator 1 GlaxoSmithKline, LLC. $13,584.60 02/05/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192161234
Principal investigator 1 Eli Lilly and Company $2,897.99 01/27/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875797
Principal investigator 1 Amgen Inc. $1,120,918.48 01/13/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246644373
Principal investigator 1 AstraZeneca UK Limited $64,862.05 01/08/2025 Non-covered Recipient Entity
C V MEHTA MD MEDICAL CORP
A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus No dispute reported 06/30/2026 1185539659
Principal investigator 1 GlaxoSmithKline, LLC. $18,081.90 01/08/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192162034